Meng Yanqiu, Huang Xianbin, Zhang Guangxin, Fu Sansan, Li Youhua, Song Jielong, Zhu Yizi, Xu Xinping, Peng Xiaodong
Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, PR China.
Jiangxi Clinical Research Center for Respiratory Diseases, Jiangxi Institute of Respiratory Diseases, The Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, PR China.
Transl Oncol. 2024 Dec;50:102150. doi: 10.1016/j.tranon.2024.102150. Epub 2024 Oct 8.
Hepatocellular carcinoma (HCC) is distinguished by its insidious onset, difficult treatment, and poor prognosis. Ribosomal Protein Lateral Stalk Subunit P0 (RPLP0) is implicated in numerous tumor progression processes. Nevertheless, the regulatory mechanism of RPLP0 in HCC progression remains unclear. Our study suggested that RPLP0 exhibits high expression levels in HCC and possesses promising diagnostic capabilities, as indicated by its area under the curve (AUC) of 0.908. Further analysis showed that RPLP0 was a significant independent prognostic factor, and elevated expression levels of RPLP0 were linked with poorer overall survival (OS) and progression-free interval (PFI) outcomes. Additionally, reducing RPLP0 levels led to a decrease in HCC cell proliferation, clonality, invasion, migration, and xenograft tumor growth, as well as an increase in apoptosis. Furthermore, our findings indicated that microRNA(miR)-450b-5p induced downregulation of RPLP0, leading to the suppression of the JAK/STAT3 pathway and consequently hindering the advancement of HCC. The study indicates that RPLP0 plays a role as a carcinogenic factor in HCC and carries important diagnostic and prognostic implications. Targeting the miR-450b-5p/RPLP0/JAK/STAT3 axis has potential clinical value in treating HCC.
肝细胞癌(HCC)具有起病隐匿、治疗困难和预后不良的特点。核糖体蛋白侧柄亚基P0(RPLP0)与众多肿瘤进展过程有关。然而,RPLP0在HCC进展中的调控机制仍不清楚。我们的研究表明,RPLP0在HCC中表现出高表达水平,并具有良好的诊断能力,其曲线下面积(AUC)为0.908。进一步分析表明,RPLP0是一个显著的独立预后因素,RPLP0表达水平升高与较差的总生存期(OS)和无进展生存期(PFI)结果相关。此外,降低RPLP0水平会导致HCC细胞增殖、克隆性、侵袭、迁移和异种移植肿瘤生长减少,以及细胞凋亡增加。此外,我们的研究结果表明,微小RNA(miR)-450b-5p诱导RPLP0下调,导致JAK/STAT3通路受到抑制,从而阻碍HCC的进展。该研究表明,RPLP0在HCC中作为致癌因子发挥作用,并具有重要的诊断和预后意义。靶向miR-450b-5p/RPLP0/JAK/STAT3轴在治疗HCC方面具有潜在的临床价值。